West Pharmaceutical Services Q2 Earnings Call Highlights

Impact · against what's priced in

West Pharmaceutical Services is seeing a structural acceleration in growth driven by high-value product (HVP) components and biologics, leading to a significant raise in 2026 guidance. The confirmation that oral GLP-1s are expanding the market rather than cannibalizing injectables removes a key potential headwind for long-term valuation.

WST+0.70

No priced-in read yet

In context

The company raised its 2026 organic growth outlook to 10%-11% (from 7%-9%) and adjusted EPS to $8.85-$9.05, supported by HVP components now reaching 49% of total revenue and a 200 bps contribution from Annex 1 upgrades.

Read from the article alone

• guidance▲9%
• earnings▲<1%
• healthcare
• WST
• biologics
• biosimilars
• cyber incident
• glp 1